Antibody-drug conjugates (ADC) are formed by the coupling of specific targeting monoclonal antibodies and highly active cytotoxic drugs through linkers. With their unique pharmaceutical properties, ADC drugs exhibit strong anti-tumor activity in the field of cancer therapy, while also offering higher safety compared to traditional chemotherapy. In recent years, the development of ADC drugs in … Read more
1 Introduction Antibody-drug conjugates (ADCs) are a new type of highly effective biopharmaceuticals that link antibodies with biologically active small molecule cytotoxic payloads through linkers. ADCs are designed to improve the therapeutic index (TI) of chemotherapeutic agents by selectively delivering cytotoxic drugs to tumor cells while reducing exposure in normal cells. Despite using a large … Read more
Basic Working Principle of ADC Source: CSDN Blogger:xtmtm ADC ( analog to digital converter ) conversion process The basic conversion principle of ADC is divided into four processes: ① Anti-aliasing filter ( Anti-aliasing ), which can be understood as a low-pass filter ② Sample and hold circuit ( Sample and hold ) ③ Quantization ( … Read more
Source: YaoDu Written by: -7℃ Edited by: Wanzi ADC (Antibody Drug Conjugate) is a complex formed by linking cytotoxic drugs to monoclonal antibodies targeting tumors, which combines the characteristics of targeted drugs and chemotherapy drugs, enabling precise treatment. The concept of ADC drugs was proposed as early as 1900, but it remained theoretical for a … Read more
*For reference only by medical professionals The latest review reports that ADC drug resistance is related to antigen expression, ADC processing, and payload efficacy. Antibody-drug conjugates (ADC) are formed by the conjugation of specific targeting monoclonal antibodies and highly active cytotoxic drugs via linkers. With their unique pharmacological properties, ADC drugs exhibit powerful anti-tumor activity … Read more
Antibody-drug conjugates (ADC) have become one of the most sought-after methods for treating cancer patients. Recently, several notable deals have taken place between small biotech companies developing ADCs and large companies looking to enhance their oncology pipelines. The recent Kangfang AK112 incident has brought bispecific antibodies into the spotlight, with some discussing the viability of … Read more
1 Introduction Antibody-drug conjugates (ADC) are an emerging technology that selectively targets cancer cells to overcome the limitations of chemotherapy. ADC binds to antigens, especially those overexpressed on the surface of cancer cells, reducing side effects caused by nonspecific targeting and improving the therapeutic index. The ideal efficacy of an ADC is entirely dependent on … Read more
So far, more than 10 types of antibody-drug conjugates (ADC) have been approved by the U.S. Food and Drug Administration (FDA) and have contributed to the medical field. Interestingly, they are all manufactured using chemical conjugation techniques. This indicates that chemical conjugation is the primary method for ADC manufacturing. Compared to other conjugation techniques such … Read more
Compiled by: Oncology Information Source: Oncology Information Antibody-drug conjugates (ADCs) are formed by linking monoclonal antibodies that target specific antigens with cytotoxic small molecule drugs, combining the targeting specificity of antibody drugs with the powerful lethality of cytotoxins. The aim is to overcome the issues of weak cytotoxicity of monoclonal antibodies and the high toxicity … Read more
After the era of chemotherapy, targeted therapy, and immunotherapy, the ADC (antibody-drug conjugate) drugs, which couple cytotoxic drugs with targeted monoclonal antibodies, have opened the era of the fourth ladder of tumor drug therapy with excellent results. They have now become a new class of drugs in tumor treatment that cannot be ignored both domestically … Read more